MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

MDT

84.12

-0.08%↓

VEEV

226.85

-0.36%↓

A

106.2

-0.66%↓

WBA

11

-0.18%↓

CHE

555.98

+1.76%↑

Search

Merus NV

Gesloten

SectorGezondheidszorg

43.51 -1.78

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

43.18

Max

43.79

Belangrijke statistieken

By Trading Economics

Inkomsten

-31M

Verkoop

9.1M

EPS

-0.49

Winstmarge

-338.326

Werknemers

260

EBITDA

-88M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+105.23% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

354M

3B

Vorige openingsprijs

45.29

Vorige sluitingsprijs

43.51

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Merus NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 apr 2025, 17:01 UTC

Winsten
Belangrijke Marktbewegers

Aon Shares Sink After 1Q Profit Falls, Sales Miss Estimates

25 apr 2025, 16:10 UTC

Winsten
Belangrijke Marktbewegers

Coursera Shares Rise After 1Q Beat, Better-Than-Expected Revenue View

26 apr 2025, 18:14 UTC

Winsten

Tech Executives Are Starting to Talk Tariffs. What It May Mean for Apple, Amazon Earnings -- Barrons.com

26 apr 2025, 15:00 UTC

Winsten
Acquisities, Fusies, Overnames

Trump 2.0 Era Brings Flurry of Crypto Deals -- WSJ

26 apr 2025, 08:20 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

25 apr 2025, 21:24 UTC

Top Nieuws

Cargo Shipments From China to the U.S. Dwindle -- WSJ

25 apr 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

25 apr 2025, 20:45 UTC

Top Nieuws

Stocks Claw Back Most of April's Tariff Losses -- WSJ

25 apr 2025, 20:39 UTC

Winsten

The Score: Tesla, Capital One, Boeing and More Stocks That Defined the Week -- WSJ

25 apr 2025, 20:37 UTC

Top Nieuws

Trump Administration Lays Out Tariff Roadmap to Streamline Trade Talks -- WSJ

25 apr 2025, 20:19 UTC

Top Nieuws

Nasdaq Climbs More Than 1% as Stocks Finish Strong Week -- WSJ

25 apr 2025, 20:15 UTC

Winsten

Week's Best: A Dividend Expert's Best Advice -- Barrons.com

25 apr 2025, 19:23 UTC

Marktinformatie

U.S. Natural Gas Futures Extend Weekly Losses -- Market Talk

25 apr 2025, 19:18 UTC

Marktinformatie

Oil Futures End Choppy Week With Losses -- Market Talk

25 apr 2025, 18:47 UTC

Marktinformatie

Gold Extends Pullback to Close Week -- Market Talk

25 apr 2025, 18:39 UTC

Top Nieuws

Nasdaq, Dow Industrials About Flat; Analysts Caution on Trump Tariffs -- WSJ

25 apr 2025, 18:34 UTC

Acquisities, Fusies, Overnames

Goldman Sachs Upgrades Schwab Stock. Here's Why. -- Barrons.com

25 apr 2025, 18:32 UTC

Marktinformatie
Winsten

Global Equities Roundup: Market Talk

25 apr 2025, 18:32 UTC

Marktinformatie
Winsten

Carriers See Tariffs Driving Up Phone Prices, Slowing Upgrades -- Market Talk

25 apr 2025, 18:08 UTC

Winsten

Sphere Entertainment Deal Is a Win for Shareholders as Banks Take a Hit -- Barrons.com

25 apr 2025, 17:55 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 483 -- Market Talk

25 apr 2025, 17:40 UTC

Top Nieuws

Consumers Continue to Sour on the Economy -- 4th Update

25 apr 2025, 17:38 UTC

Winsten

Centene Stock Falls on Medicaid Cost Worries -- Barrons.com

25 apr 2025, 17:07 UTC

Marktinformatie

Oil Futures Turn Higher in Quiet Trade -- Market Talk

25 apr 2025, 16:54 UTC

Marktinformatie
Winsten

Mobile Carriers See Stronger Activity on Bigger Price Tags, Tariffs -- Market Talk

25 apr 2025, 16:46 UTC

Winsten

Reddit, Meta, and Pinterest Stocks Rise. How Alphabet's Earnings Are Giving Them a Boost. -- Barrons.com

25 apr 2025, 16:20 UTC

Marktinformatie
Winsten

Basic Materials Roundup: Market Talk

25 apr 2025, 16:12 UTC

Top Nieuws

Dow Industrials Fall; China Plans Economic Support During Trade Battle -- WSJ

25 apr 2025, 16:03 UTC

Winsten

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25 apr 2025, 15:52 UTC

Marktinformatie

Grains Mixed on Low Volume Trade -- Market Talk

Peer Vergelijking

Prijswijziging

Merus NV Prognose

Koersdoel

By TipRanks

105.23% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 89.42 USD  105.23%

Hoogste 110 USD

Laagste 67 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Merus NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

15

Buy

0

Hold

0

Sell

Technische score

By Trading Central

43.215 / 44.36Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.